greeksoup/ stock research

Teladoc Health (TDOC) Q2 FY2024 earnings: revenue $642 million, down 1.5% on the year

Teladoc Health, Inc. (TDOC) reported revenue of $642 million for Q2 FY2024, the quarter ended 30 June 2024, down 1.5% on the same quarter a year earlier. Net income was -$838 million, and diluted earnings per share $-4.92. The figures are the company's own, from the 10-Q it filed with the SEC on 1 August 2024.

Revenue$642 milliondown 1.5%
Net income-$838 million
Diluted EPS$-4.92
QuarterQ2 FY2024ended 30 June 2024

The quarter, against the one before and a year earlier

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Revenue642646652-1.5%
Cost of revenue188195191-1.3%
Gross profit454452462-1.6%
Gross margin70.7%69.9%70.8%
Research and development76.881.487.3-12.1%
Operating income-841-87.1-71.6n/a
Operating margin-130.9%-13.5%-11.0%
Interest expense5.65.65.8-3.2%
Pre-tax income-834-79.2-66.1n/a
Income tax3.92.7-1.0n/a
Net income-838-81.9-65.2n/a
Net margin-130.4%-12.7%-10.0%
Diluted EPS-$4.92-$0.49-$0.40n/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Operating cash flow88.78.9101-12.4%
Capital expenditure1.91.11.9+0.4%
Free cash flow86.87.899.3-12.6%
Free cash flow margin13.5%1.2%15.2%
Cash from investing-27.7-35.5-36.6n/a
Cash from financing3.81.84.2-9.6%
Depreciation and amortisationn/an/a75.5n/a
Share-based compensation42.142.355.7-24.4%
Diluted shares, weighted170m168m164m+3.7%
Shares outstanding at period end171m169m165m+3.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Shareholders' equity1,5022,2892,295-34.6%
Debt1,5401,5401,537+0.2%
Operating lease liabilities37.740.036.8+2.5%
Other liabilities443452447-0.9%
Total liabilities and equity3,5244,3214,316-18.4%
Fixed assets29.329.630.4-3.5%
Goodwill2831,0731,073-73.6%
Intangible assets1,5471,6141,784-13.3%
Cash and equivalents1,1621,098959+21.2%
Receivables218214215+1.5%
Inventory34.932.334.1+2.5%
Other assets248259221+12.3%
Total assets3,5244,3214,316-18.4%

Questions

What was Teladoc Health's revenue in Q2 FY2024?

Teladoc Health (TDOC) reported revenue of $642 million for Q2 FY2024, the quarter ended 30 June 2024, down 1.5% on the same quarter a year earlier.

How much did Teladoc Health earn in Q2 FY2024?

Net loss for Q2 FY2024 was $838 million, and the diluted loss per share $4.92.

When did Teladoc Health report Q2 FY2024 results?

Teladoc Health filed its 10-Q for the quarter ended 30 June 2024 with the SEC on 1 August 2024.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022Q2 FY2022 †Q3 FY2022 †Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue554565592611638629652660661646642641640629632626642614607605
Cost of revenue175187182186189190191186193195188180189197191187197198191190
Gross profit379378410426449439462474467452454461452433441439445416416415
Gross margin68%67%69%70%70%70%71%72%71%70%71%72%71%69%70%70%69%68%69%69%
R&D72.987.478.784.677.687.087.384.389.981.476.872.476.870.068.867.671.667.962.965.5
Operating income-41.4-6,669-3,097-71.7-3,816-77.1-71.6-64.7-35.1-87.1-841-44.4-48.2-121-54.4-52.0-36.0-61.8-37.1-28.1
Operating margin-7%-1180%-523%-12%-598%-12%-11%-10%-5%-13%-131%-7%-8%-19%-9%-8%-6%-10%-6%-5%
Interest expensen/an/a5.66.1n/a5.35.85.65.55.65.65.76.85.84.54.55.05.45.14.9
Pre-tax income-60.7-6,674-3,103-74.6-3,812-68.5-66.1-59.6-25.4-79.2-834-32.5-48.2-111-40.4-50.2-33.6-60.8-37.9-26.3
Net income-11.0-6,675-3,101-73.5-3,810-69.2-65.2-57.1-28.9-81.9-838-33.3-48.4-93.0-32.7-49.5-25.1-63.8-38.9-26.9
Net margin-2%-1181%-524%-12%-597%-11%-10%-9%-4%-13%-130%-5%-8%-15%-5%-8%-4%-10%-6%-4%
Diluted EPS-$0.03-$41.58-$19.22-$0.45-$23.49-$0.42-$0.40-$0.35-$0.17-$0.49-$4.92-$0.19-$0.28-$0.53-$0.19-$0.28-$0.14-$0.36-$0.21-$0.15
Operating cash flow83.2-31.792.563.065.513.21011061308.988.711085.915.991.499.387.79.564.7106
Capital expenditure2.93.92.53.86.22.41.95.81.41.11.91.66.12.71.32.32.61.70.91.2
Free cash flow80.3-35.789.959.259.410.899.399.81297.886.810979.813.290.297.085.17.963.7105
Shares outstanding160m161m162m162m163m164m165m166m167m169m171m172m173m175m177m177m178m180m182m182m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 June 2024, filed 1 August 2024: the filing.